Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 268
Selected: 0
NCT IDTitle
NCT06506773Natural History Study of Exocrine Pancreatic Function in Infants With Cystic Fibrosis (CF)
NCT02514473A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation
NCT01241760VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection
NCT06619860Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy
NCT05347394A Phase 1 Dose Escalation Study of Oral VX-708 in Healthy Participants
NCT04340362Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis
NCT03447262A Study Evaluating the Long Term Safety and Efficacy of VX-659 Combination Therapy
NCT03859531Gastrointestinal Study at Orkambi Therapy in CF Patients
NCT00909727Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation
NCT05444257A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
NCT00789126Single and Multiple Dose Escalation Study of VX-509 in Healthy Subjects
NCT00627926A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)
NCT05851157A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548
NCT02951182A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis
NCT03061331Lumacaftor/Ivacaftor Combination Therapy in Subjects With CF Who Have an A455E CFTR Mutation
NCT05579431A Phase 1, First-in-human Study of VX-634
NCT03525574A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
NCT02875366A Study of the Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation
NCT01060566Study of VX-770 on Midazolam and Rosiglitazone and the Effect of Fluconazole on VX-770
NCT03633526Evaluation of VX-659/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age
NCT05553366Evaluation of Efficacy and Safety of VX-548 for Acute Pain After a Bunionectomy
NCT04599465A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)
NCT06887972A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries
NCT04006873Gut Imaging for Function & Transit in Cystic Fibrosis Study 2
NCT04058366Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
NCT01531673Study of VX-661 Alone and in Combination With Ivacaftor in Subjects Homozygous or Heterozygous to the F508del-Cystic Fibrosis Transmembrane Conductance Regulator(CFTR) Mutation
NCT01054573VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo
NCT02722057A Study to Confirm the Long-term Safety and Effectiveness of Kalydeco in Patients With Cystic Fibrosis Who Have an R117H-CFTR Mutation, Including Pediatric Patients
NCT03525444A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
NCT04058210VX-445/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients Heterozygous for F508del Mutation and a Minimal Function Mutation (F/MF Genotypes)
NCT03768089Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis
NCT02070744Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion
NCT04786262A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
NCT01467492Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C
NCT04138589Effect of Lumacaftor/Ivacaftor in Children With Cystic Fibrosis Homozygote for F508del on Small Airway Function
NCT04208529A Long-term Follow-up Study in Participants Who Received CTX001
NCT05033080A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)
NCT06508762A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation of VX-993
NCT01052194A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis
NCT03125395A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
NCT03338595Longitudinal Assessment of Exercise Capacity and Vascular Function in Patients With CF
NCT05643495A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype
NCT02951195A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis
NCT01863238An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis
NCT05660538Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)
NCT03625466A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del
NCT05422222Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of Age
NCT03783286Ivacaftor Treatment in 4 Month to 2 Year Old CF Subjects
NCT02971839Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations
NCT01931839A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis